Anti‐<scp>SPAG</scp>16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index

Abstract

Anti-SPAG16 antibodies are associated with an increased EDSS in overall MS, indicating that they are linked to a worse MS disease outcome. Moreover, the presence of anti-SPAG16 antibodies may be a biomarker for a more severe disease in PPMS patients, as indicated by an increased progression index.